Biotronik today touted study results showing that its hybrid Orsiro drug-eluting stent may have the edge on the Xience Prime and Xience Xpedition stents made by Abbott (NYSE:ABT) in patients with a certain kind of heart attack.*
Published in the journal EuroIntervention, a sub-analysis from the Bioscience trial of 407 patients with ST-segment elevation myocardial infarctions showed that the rate of target lesion failure after a year was 3.3% for the Orsiro-treated population and 8.7% in the Xience group.
“With these extremely promising results for the Bioscience trial’s STEMI patients in hand, it is now time to demonstrate Orsiro’s far-reaching capabilities with a much larger randomized, controlled trial specifically focused on this indication,” Biotronik vascular intervention marketing VP Alexander Uhl said in prepared remarks. “In an effort to shed light on the superb efficacy of Orsiro in this challenging patient population, we expect to begin enrolling patients to the BioSTEMI trial soon.”
“During the Bioscience trial, Orsiro was associated with a significantly reduced risk of the primary endpoint of TLF for STEMI patients,” added lead author Dr. Thomas Pilgrim of Bern, Switzerland’s University Clinic for Cardiology. “We hypothesize this is due to Orsiro’s bioabsorbable polymer, which might provide favorable results on arterial healing after implantation. The effect of an enhanced healing response may be more pronounced in the inflammatory milieu of STEMI. As we currently have only limited data available on the clinical performance of newer generation DES in STEMI patients, we will soon attempt to extend these results in a dedicated randomized trial known as BioSTEMI.”
*Correction, Feb. 22, 2016: This article originally referred to the Xience devices as being made by Boston Scientific. We regret the error. Return to the corrected sentence.
